ReWalk Receives Court Approval For Share Repurchase Program

ReWalk Robotics Ltd. (NASDAQ:RWLK) (the "Company" or "ReWalk"), a leading manufacturer of robotic medical technology for people with lower extremity disabilities, today announced that it has received

ReWalk Robotics Ltd. (NASDAQ:RWLK) (the “Company” or “ReWalk”), a leading manufacturer of robotic medical technology for people with lower extremity disabilities, today announced that it has received Israeli court approval to repurchase up to $8 million of its Ordinary Shares, par value NIS 0.25 per share. The court approval is valid through January 20, 2023.
 

Under the program, share repurchases may be made from time to time using a variety of methods, including open market transactions or in privately negotiated transactions. Such repurchases will be made in accordance with all applicable securities laws and regulations, including restrictions relating to volume, price and timing under applicable law, including Rule 10b-18 under the United States Securities Exchange Act of 1934, as amended (the “1934 Act”). The timing and amount of shares repurchased will be determined by the Company’s management, within guidelines to be established by the Board or a committee thereof, based on its ongoing evaluation of ReWalk’s capital needs, market conditions, the trading price of the Company’s shares, trading volume and other factors, subject to applicable law. For all or a portion of the authorized repurchase amount, ReWalk may enter into a plan compliant with Rule 10b5-1 under the 1934 Act that is designed to facilitate these repurchases.

The repurchase program does not require ReWalk to acquire a specific number of shares, and may be suspended or discontinued at any time. The share repurchases will be funded from available working capital.

Total
0
Shares
Related Posts
Read More

Jaguar Health Enters Exclusive Crofelemer Revenue Sharing License And Commercialization Agreement With Quadri Pharmaceuticals Store For Rare Intestinal Failure Diseases In Middle East Markets

Quadri Pharma will cover 50% of the costs of development activity up to a capped dollar contributionJaguar to host virtual educational webinar on intestinal failure with leading gastroenterologists and nutrition experts

JAGX